Orion Office REIT Inc (ONL) Stock Price Today
Replimune's melanoma drug gets FDA nod but faces legal probe over data practices
Replimune Group's melanoma drug Tudriqev received accelerated FDA approval after two prior rejections, based on a 24.20% response rate in trials. Following this, BMO Capital raised its price target for Replimune stock from $16 to $20, indicating stro...
Digital Realty backs Texas Governor Abbott's plan for responsible data center growth amid rising AI demand.
Digital Realty, the largest cloud- and carrier-neutral data center platform, supports Texas Governor Abbott's initiative for responsible and transparent data center investment in Texas. The company emphasizes collaboration with officials and communit...
Verisk Analytics CEO Lee Shavel sells 2,500 shares for $550,000.
Verisk Analytics CEO Lee Shavel has sold 2,500 shares of the company, generating $550,000 from the transaction. This sale may indicate personal portfolio adjustments or strategic financial planning by the CEO. Investors might watch for any further in...
Replimune's stock jumps after FDA approves its first skin cancer drug Tudriqev
Replimune Group Inc. received FDA approval for Tudriqev, its first drug targeting a difficult form of skin cancer, marking a major milestone for the biotech company. Despite earlier rejections and concerns over clinical data quality, the FDA granted ...
Trade Desk shares drop nearly 30% after Q2 revenue and profit miss estimates, with weak Q3 forecast.
Trade Desk's shares fell almost 30% in premarket trading after the company reported second-quarter revenue of $715 million, missing the $751 million analyst estimate, and adjusted earnings per share of $0.34, below the expected $0.40. The company als...
Man Group PLC discloses 0.57% stake in Bodycote Plc, reducing long equity swap positions.
Man Group PLC has publicly disclosed holding a 0.57% interest in Bodycote Plc as of August 6, 2026. The disclosure reveals that Man Group is reducing its long positions through multiple equity swap transactions at varying prices. This update is part ...
Amylyx shifts focus to endocrine drug avexitide with strong cash runway into 2028 and key trial results in 2026
Amylyx Pharmaceuticals is transitioning from its previous focus on ALS treatments to developing avexitide, a late-stage endocrine drug targeting post-bariatric hypoglycemia, a large orphan market with no approved therapies. The company has $250.8 mil...
Tech stocks rally as weak July jobs report boosts SpaceX, Palantir, and Cloudflare shares.
Major tech stocks surged following a weaker-than-expected jobs report for July, which showed a drop in payrolls. SpaceX shares jumped 11% from a recent low, despite being down 16% since their June debut. Palantir rose 8.4%, continuing a strong weekly...
ADW Capital demands Driven Brands board start immediate public sale process amid valuation dispute.
ADW Capital Management, holding about 4.8% of Driven Brands, publicly urged the company's board and controlling shareholder Roark Capital to initiate an immediate public sale or strategic review of the company. ADW criticized the board for rejecting ...
Convergence Long/Short Equity ETF (CLSE) outperforms peers with balanced tech exposure and lower volatility.
The Convergence Long/Short Equity ETF (CLSE) uses a mix of quantitative and fundamental strategies to hold long and short positions across about 3,000 U.S. stocks. Its short positions focus on expensive, weaker companies with higher price-to-earnings...
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.